drugset / Trial / NCT06886347
Metastatic Nasopharyngeal Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
To evaluaate the efficacy and safety of the regimen incuding Penpulimab, Gemcitabine and Anlotinib in the treatment of metastatic nasopharyngeal carcinoma. Using Progression-Free-Survival as the primary endpoint.
Timeline
- Start
- 2023-07-07
- Primary completion
- 2026-04-01
- Completion
- 2026-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Antitinib Hydrochloride | Unknown | 10 mg | Oral |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | Penplimab | Unknown | 200 mg | Intravenous |